NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $19.14 +0.59 (+3.18%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$18.55▼$19.2150-Day Range$14.62▼$18.6252-Week Range$14.55▼$32.59Volume2.36 million shsAverage Volume1.77 million shsMarket Capitalization$3.16 billionP/E RatioN/ADividend YieldN/APrice Target$28.59 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ACADIA Pharmaceuticals alerts: Email Address ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.76 Rating ScoreUpside/Downside49.4% Upside$28.59 Price TargetShort InterestHealthy6.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.52Based on 12 Articles This WeekInsider TradingSelling Shares$348,697 Sold Last QuarterProj. Earnings Growth79.31%From $0.58 to $1.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.25 out of 5 starsMedical Sector158th out of 936 stocksPharmaceutical Preparations Industry65th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 13 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.86% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 5.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.0 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for ACADIA Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 11 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $348,697.00 in company stock.Percentage Held by Insiders28.30% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 79.31% in the coming year, from $0.58 to $1.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -1,912.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -1,912.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 7.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesJuly 26 at 3:22 AM | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Post FY2024 Earnings of $0.38 Per Share, Cantor Fitzgerald ForecastsJuly 25 at 10:38 PM | finance.yahoo.comACAD Aug 2024 25.000 call (ACAD240816C00025000)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 9:53 AM | finance.yahoo.comMarvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett SyndromeJuly 23 at 6:22 AM | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded by StockNews.com to BuyJuly 19, 2024 | markets.businessinsider.comAcadia Pharma Reveals Positive Data From Daybue Studies In Rett SyndromeJuly 17, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Down 5.5% in JuneJuly 2, 2024 | stocknews.com3 Mid-Cap Stocks Analysts Believe Will Soar 50% or MoreJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 23, 2024 | seekingalpha.comAcadia Pharmaceuticals: Back In The Buy ZoneJune 18, 2024 | businesswire.comAcadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific MeetingJune 18, 2024 | businesswire.comNew Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost SavingsJune 5, 2024 | seekingalpha.comAcadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS TreatmentsMay 27, 2024 | finanznachrichten.deNeuren Pharmaceuticals Ltd: Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndromeMay 23, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)May 17, 2024 | businesswire.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 17, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS) and Elicio Therapeutics (ELTX)May 15, 2024 | stocknews.com3 Pharma Stocks to Buy for Potential Financial FortunesSee More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$28.59 High Stock Price Target$42.00 Low Stock Price Target$19.00 Potential Upside/Downside+49.4%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio33.00 P/E GrowthN/ANet Income$-61,290,000.00 Net Margins-0.21% Pretax Margin1.83% Return on Equity-0.41% Return on Assets-0.24% Debt Debt-to-Equity RatioN/A Current Ratio2.04 Quick Ratio1.86 Sales & Book Value Annual Sales$726.44 million Price / Sales4.35 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book7.28Miscellaneous Outstanding Shares165,220,000Free Float118,463,000Market Cap$3.16 billion OptionableOptionable Beta0.38 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 63)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 55)Executive VP, COO & Head of Commercial Comp: $724.31kMr. James K. Kihara (Age 43)VP, Chief Accounting Officer & Corporate Controller Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Executive VP & Head of Research and Development Mr. Benir RuanoSenior Vice President of Technical Development & OperationsMr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsMs. Jennifer J. Rhodes J.D. (Age 54)Executive VP, Chief Legal Officer & Secretary Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyMs. Holly ValdiviezSenior VP & Head of SalesMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCMirati TherapeuticsNASDAQ:MRTXInsmedNASDAQ:INSMLegend BiotechNASDAQ:LEGNCatalentNYSE:CTLTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 22,513 shares on 7/26/2024Ownership: 0.318%Allspring Global Investments Holdings LLCBought 49,992 shares on 7/26/2024Ownership: 0.066%AlphaCentric Advisors LLCBought 55,000 shares on 7/26/2024Ownership: 0.061%Hennion & Walsh Asset Management Inc.Sold 40,521 shares on 7/20/2024Ownership: 0.062%China Universal Asset Management Co. Ltd.Sold 12,244 shares on 7/20/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $31.31 on January 1st, 2024. Since then, ACAD stock has decreased by 38.9% and is now trading at $19.14. View the best growth stocks for 2024 here. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.06. The business's revenue was up 73.8% compared to the same quarter last year. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. Who are ACADIA Pharmaceuticals' major shareholders? Top institutional investors of ACADIA Pharmaceuticals include Bank of New York Mellon Corp (0.32%), M&G Plc (0.21%), Neo Ivy Capital Management (0.12%) and Allspring Global Investments Holdings LLC (0.07%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Srdjan R Stankovic, Austin D Kim, Brendan Teehan, Mark C Schneyer, James Kihara and Laura Brege. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA) and Alibaba Group (BABA). This page (NASDAQ:ACAD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
